So, even though the total drug level in our blood is in the nanomolar range, its so tightly bound to protein that the active level in our blood thats free to actually interact with tissue receptors is like a hundred times smaller, at least down in the picomolar range
What is missing: randomized controlled trials of systemic GHK-Cu supplementation measuring clinically relevant aging outcomes
Long-term data confirm robust effects on mortality, cardiometabolic outcomes, renal disease, T2D progression, musculoskeletal function, sleep apnea, liver disease, and cancer risk
Other risk factors, including diabetes, hypertension, hyperlipidemia and obstructive sleep apnea, are some of the very reasons why a patient might start taking a GLP-1RA
Your prescriber can coordinate the transition to ensure continuity of therapy